Euroopa Liit -
eesti -
EMA (European Medicines Agency)
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaktsiinid - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaktsiinid - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
vidprevtyn beta
sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaktsiinid - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 ja 5. 1 in product information document). kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
bimervax
hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaktsiinid - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
jaypirca
eli lilly nederland b.v. - pirtobrutinib - lümfoom, mantle-cell - protein kinase inhibiitorid - treatment of mantle cell lymphoma (mcl).
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
clopidogrel bgr (previously zylagren)
biogaran - clopidogrel (as hydrogen sulfate) - peripheral vascular diseases; stroke; myocardial infarction - antitrombootilised ained - ennetamine atherothrombotic sündmuste clopidogrel on näidustatud:täiskasvanud patsientidel, kes põevad müokardiinfarkt (paar päeva kuni vähem kui 35 päeva), ischaemic insult (7 päeva kuni vähem kui 6 kuud) või väljakujunenud perifeersete arterite haigus.
Eesti -
eesti -
Ravimiamet
no-spa tablett
opella healthcare france s.a.s. - drotaveriin - tablett - 40mg 20tk; 40mg 24tk
Eesti -
eesti -
Ravimiamet
no-spa süstelahus
opella healthcare france s.a.s. - drotaveriin - süstelahus - 20mg 1ml 2ml 25tk; 20mg 1ml 2ml 5tk
Eesti -
eesti -
Ravimiamet
guttalax suukaudsed tilgad, lahus
opella healthcare france s.a.s. - naatriumpikosulfaat - suukaudsed tilgad, lahus - 7,5mg 1ml 15ml 1tk; 7,5mg 1ml 30ml 1tk
Eesti -
eesti -
Ravimiamet
no-spa õhukese polümeerikattega tablett
opella healthcare france s.a.s. - drotaveriin - õhukese polümeerikattega tablett - 40mg 24tk